Refine by
Antigen Expression Suppliers Near Namibia
28 companies found
based inSouth San Francisco, CALIFORNIA (USA)
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific ...
Sutro’s cell-free expression technology provides a rapid and powerful platform for the discovery and development of next generation antibody-drug conjugates ...
based inGroningen, NETHERLANDS
ViciniVax is a Dutch clinical stage biopharmaceutical company. It is a spin-off from the University Medical Center Groningen, the Netherlands, developing therapeutic cancer vaccines. Our first product candidate Vvax001, a therapeutic cancer vaccine ...
Our first product candidate Vvax001, a therapeutic cancer vaccine against (pre)malignant cervical lesions, is currently in clinical development. We outsource process development and GMP manufacturing to experienced CMO’s, leading to a first ...
based inIndianapolis, INDIANA (USA)
One of the largest inhibitors to the advancement of translational research is a lack of specific reagents, antibodies, analytes, and support services for those scientists involved in the early stages of research and development using animal models. ...
Regenerative medicine is a discipline of medicine that focuses on the repair or replacement of damaged or diseased cells or tissues. Many institutions are developing novel methods to use naturally occurring cells, transgenic cells, ...
based inGosselies, BELGIUM
SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world's first rat myeloma cell line. SYnAbs' vision is to fill the gap on the marketplace for ...
Transmembrane proteins are probably the most complex and challenging antigens to target with monoclonal antibodies. Indeed, despite their strong presence in the animal kingdom and their implications in many cellular mechanisms, they remain very ...
based inRedwood City, CALIFORNIA (USA)
Meissa Vaccines was founded with a mission to protect people everywhere from deadly respiratory viruses and a commitment to develop innovative technologies capable of delivering effective vaccines at a global scale. Meissa is developing live ...
AttenuBlock is Meissa's proprietary platform that uses synthetic biology – the area of science focused on redesigning natural organisms to give them new abilities – to generate live attenuated RSV vaccine candidates designed to increase ...
based inCambridge, MASSACHUSETTS (USA)
Myeloid Therapeutics is a leader in the development of mRNA-based immunotherapies, focusing on harnessing and enhancing the natural capabilities of myeloid cells to combat cancer. The company's cutting-edge in vivo engineering platform is designed ...
Emerging from the Company’s proprietary ATAK™ CAR receptor library, Myeloid’s novel in vivo engineering platform specifically targets and activates myeloid cells to elicit broader anti-tumor adaptive immunity. Through this ...
based inSeattle, WASHINGTON (USA)
Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative ADAPTIR™ and ADAPTIR-FLEX platform technologies to create therapeutic candidates designed to improve outcomes for ...
ALG.APV-527 is a bispecific antibody candidate targeting 4-1BB x 5T4 and is intended for tumor-directed treatment of solid cancers. It was built using Aptevo’s ADAPTIR™ bispecific technology platform and combines binding domains sourced ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
The Dolaflexin platform was designed to increase the efficacy, safety, and tolerability of ADCs. This platform overcomes the limitations of traditional ADCs in which drugs are directly conjugated to antibodies. Dolaflexin utilizes our proprietary ...
based inSan Diego, CALIFORNIA (USA)
Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions. Stemedica has developed a proprietary ...
Stemedica’s manufacturing technology is not Stemedica’s only advantage. Our cells undergo a battery of tests, monitoring and analysis to ensure the highest-quality cells that will operate predictably under clinical, pre-clinical, or ...
based inWürzburg, GERMANY
Toleris Biotherapeutics GmbH is a biotechnology company based in Würzburg, Germany. The company specializes in the development of innovative biotherapeutic solutions aiming to advance the field of medicine through cutting-edge scientific research. ...
AIM Bio has developed a platform of Autoimmunity Modifying Biologicals (AIM Biologicals) that uses soluble, near-physiological proteins to induce selective, antigen-specific immune tolerance. These proteins mimic a natural process observed in ...
based inHeidelberg, GERMANY
We are a team of passionate, experienced individuals who work every day to improve the lives of patients. Led by an expert team of biotechnology and pharmaceutical professionals, we are united by one goal—to stop cancer from ever derailing patients’ ...
AFM24, an EGFR-directed ICE® (innate cell engager) molecule, represents a distinctive mechanism that engages innate immune cells by recruiting NK cells and macrophages to the site of the tumor for effective and efficient tumor-cell killing. ...
based inLa Vista, NEBRASKA (USA)
Streck is an ISO-certified biotech company with proven proprietary science and an unwavering commitment to the highest standards in developing and manufacturing Quality Control and diagnostic products in hematology, immunology, molecular ...
Cyto-Chex BCT is a direct draw blood collection tube for the collection and storage of whole blood specimens for immunophenotyping of white blood cells by flow cytometry. Cyto-Chex BCT has been FDA 510(k) cleared for consistent recovery of ...
based inSeattle, WASHINGTON (USA)
Universal Cells is a Seattle-based company that is producing engineered stem cell lines that can avoid rejection and be used in allogeneic cell therapy treatments for the people who need them. One Cell, Many Therapies. Universal Cells edits genes ...
Realizing the potential of pluripotent stem cells requires that the therapeutic cells derived from PSCs be accepted by patients. PSC-derived cells that have not been engineered to avoid allogeneic rejection will be eliminated soon after ...
based inSouth San Francisco, CALIFORNIA (USA)
Senti Bio was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti Bio designs and optimizes gene circuits, which are created from novel and proprietary ...
Senti Bio has established, and continues to scale, a powerful Design-Build-Test-Learn development engine to generate our therapeutic gene circuits. Unique to Senti Bio’s approach is the speed, quantity and quality of the multiple types of gene ...
based inDavis, CALIFORNIA (USA)
Located in Davis, CA, Aves Labs develops novel antibody reagents against neural-specific antigens and epitope tags to foster scientific progress in neuroscience and the molecular biology communities. Aves Labs was co-founded in 1995 by Gary Ciment ...
Human Glial Fibrillary Acidic Protein (GFAP) is a 49,749 dalton protein (432 amino acids) expressed by astrocytes of the central nervous system. GFAP is an intermediate filament protein and acts as an intra-cellular structural component of the ...
based inRehovot, ISRAEL
ProSpec is an evolving biotech company providing highly purified proteins worldwide which serve the research community with cytokine-related products for cancer, apoptosis, development, endocrinology, immunology, neuroscience, proteases, and stem ...
TNFSF9 Human Recombinant fused to 37 amino acids His tag at N-terminus produced in E.Coli is a single, non-glycosylated polypeptide chain containing 222 amino acids (71-254 a.a.) and having a molecular mass of 23.8 kDa. The TNFSF9 37 aa His tag ...
based inHolliston, MASSACHUSETTS (USA)
BTX has been at the forefront of electroporation technology since we introduced the first commercially available electroporator in 1983. For over 30 years, we have made it our priority to focus only on electroporation and electrofusion. This focus ...
The AgilePulse In Vivo System, used for animal immunization, vaccine development, and gene therapy, provides an intra-muscular, intra-dermal, or intra-tumor electroporation solution to produce maximum transfection efficiency. Traditional in vivo ...
based inNavi Mumbai, INDIA
Yashraj Biotech Limited manufactures a wide range of high pure biomarkers in the form of native and recombinant proteins that are used by the diagnostic industry as controls, calibrators and immunogens. YBL has been the preferred partner of most of ...
Research, development and large scale production of native proteins customized to meet customer’s specifications, for use in diverse biological applications (as controls, calibrators, immunogens ...
based inParis, FRANCE
Enterome is pioneering the discovery and development of novel pharmaceuticals based on its unrivalled understanding of the interaction between the gut microbiome and the immune system – the Microbiome-Immunoinflammation Axis. Enterome is using this ...
EO2401 is an innovative, off-the-shelf immunotherapy discovered by ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
We are developing CYNK-101 as a combination treatment for multiple cancer indications. CYNK-101 is manufactured from a specific type of immune cell, NK cells, that we extract from postpartum placentas and then genetically engineer to increase cell ...